A Trial to Evaluate the Effect of Food on LEO 152020
A Phase 1, Randomised, Oral Dose Trial to Evaluate the Effect of Food on LEO 152020 in Healthy Adult Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Leeds, United Kingdom
- LEO Pharma Investigational Site
-
-
-
-
Texas
-
Dallas, Texas, United States, 75247
- LEO Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key inclusion Criteria:
- Body mass index (BMI) between 18.0-32.0 kg/m2 (both inclusive)
- In good health at screening and check-in as judged by the investigator based on medical history, physical examination, vital signs assessment, 12-lead ECG, and clinical laboratory evaluations.
- Pulse rate of 50 to 100 bpm at screening, or with minor deviations judged to be acceptable by the investigator
- Females of child bearing potential and male subjects whose partners are of child-bearing potential must also agree to use an additional effective method of contraception.
Key exclusion Criteria:
- Subjects who do not, or whose partners do not agree to use effective method(s) of contraception from the time of the first dose until 3 months (90 days) after the final dose.
- Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug.
- History of any significant infectious disease within 2 weeks prior to drug administration as assessed by the investigator.
- Subjects who have received any medication within 14 days of the first dose administration, except for hormonal contraception.
- Subjects who are still participating in a clinical trial (e.g. attending follow-up visits) or who have participated in a clinical trial involving administration of an investigational drug (new chemical entity), or a marketed drug within the past 3 months prior to the first dose.
- ECG abnormalities at screening or check-in
- Heart rate of <50 or >100 beats per minute, unless the investigator judges the subject to be eligible for inclusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Fed
Single oral dose given after a full breakfast
|
film-coated tablet
|
|
Experimental: Fasting
Single oral dose given in fasting state
|
film-coated tablet
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cmax
Time Frame: pre-dose to 48 hours of each treatment period (Day 1 and Day 8)
|
Maximum observed plasma concentration
|
pre-dose to 48 hours of each treatment period (Day 1 and Day 8)
|
|
AUC (0 to infinity)
Time Frame: pre-dose to 48 hours of each treatment period (Day 1 and Day 8)
|
Area under the plasma concentration time curve (AUC) from time 0 extrapolated to infinity (AUC0 inf)
|
pre-dose to 48 hours of each treatment period (Day 1 and Day 8)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of total adverse events (AEs) and number of subjects with AEs at each combination of treatment and period
Time Frame: Baseline to Day 10
|
Number of AEs per subject at each combination of treatment and in total
|
Baseline to Day 10
|
|
Number of subjects with clinically relevant changes in vital signs (resting blood pressure)
Time Frame: Baseline to Day 10
|
Clinically relevant changes in resting blood pressure (mmHq)
|
Baseline to Day 10
|
|
Number of subjects with clinically relevant changes in vital signs (pulse)
Time Frame: Baseline to Day 10
|
Clinically relevant changes in pulse (beats per minute)
|
Baseline to Day 10
|
|
Number of subjects with clinically relevant changes in vital signs (oral body temperature)
Time Frame: Baseline to Day 10
|
Clinically relevant changes in oral body temperature (fahrenheit/celsius)
|
Baseline to Day 10
|
|
Number of subjects with laboratory abnormalities in chemistry parameters
Time Frame: Baseline to Day 10
|
Clinically relevant abnormalities in any chemistry laboratory parameters tested (standard units): Sodium, potassium, creatinine, creatine phosphokinase, urea nitrogen, calcium , alkaline phosphatase , aspartate aminotransferase , alanine aminotransferase , gamma glutamyl transferase , bilirubin, lactate dehydrogenase, cholesterol, triglycerides, glucose (fasting), albumin, protein, or tryptase
|
Baseline to Day 10
|
|
Number of subjects with laboratory abnormalities in haematology parameters
Time Frame: Baseline to Day 10
|
Clinically relevant abnormalities in any haematology laboratory parameter tested (standard units): erythrocytes, hematocrit, hemoglobin, or white blood cells
|
Baseline to Day 10
|
|
Number of subjects with laboratory abnormalities in urinalysis parameters
Time Frame: Baseline to Day 10
|
Clinically relevant laboratory abnormalities in any urinalysis parameters (standard units): protein, glucose, ketones, occult blood, leukocytes, or nitrite
|
Baseline to Day 10
|
|
Number of subjects with abnormal ECGs
Time Frame: Baseline to Day 10
|
Abnormal ECGs (maximum QTcF interval of ≥450 msec, or maximum change from baseline of ≥60 msec)
|
Baseline to Day 10
|
|
AUC (0 to last)
Time Frame: pre-dose to 48 hours of each treatment period (Day 1 and Day 8)
|
Area under the plasma concentration time curve (AUC) from time 0 extrapolated to infinity (AUC0 inf)
|
pre-dose to 48 hours of each treatment period (Day 1 and Day 8)
|
|
tmax
Time Frame: pre-dose to 48 hours of each treatment period (Day 1 and Day 8)
|
Time to maximum plasma concentration
|
pre-dose to 48 hours of each treatment period (Day 1 and Day 8)
|
|
t 1/2
Time Frame: pre-dose to 48 hours of each treatment period (Day 1 and Day 8)
|
Terminal elimination half life
|
pre-dose to 48 hours of each treatment period (Day 1 and Day 8)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Medical Expert, LEO Pharma
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- LP0190-1487
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.